ARTICLE | Company News
BioMed X, Roche parter to treat immune-mediated diseases
March 16, 2018 4:55 PM UTC
BioMed X GmbH (Heidelberg, Germany) and Roche (SIX:ROG; OTCQX:RHHBY) partnered to develop treatments for undisclosed immune-mediated diseases. BioMed X will launch a global call for applications to establish a new biomedical research group. Final winners will be offered a two- to four-year fellowship at the BioMed X Innovation Center in Heidelberg.
BioMed X said that it will own all IP during the program. Roche has an option to IP generated during the project for an undisclosed pre-negotiated flat fee...